J
John G.F. Cleland
Researcher at National Institutes of Health
Publications - 1276
Citations - 125527
John G.F. Cleland is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Heart failure & Ejection fraction. The author has an hindex of 137, co-authored 1172 publications receiving 110227 citations. Previous affiliations of John G.F. Cleland include Northwestern University & Imperial College London.
Papers
More filters
Journal ArticleDOI
Cardiac resynchronization therapy update: evolving indications, expanding benefit?
TL;DR: Whether CRT is effective in patients with atrial fibrillation or whether adding a defibrillator function to CRT improves prognosis awaits further evidence.
Journal ArticleDOI
Predicting mortality after hospitalisation for COPD using electronic health records.
TL;DR: In this paper , a pragmatic, parsimonious multivariable model was developed to predict 90-day mortality for patients hospitalised with chronic obstructive pulmonary disease (COPD).
Journal ArticleDOI
Revascularization in ischaemic heart failure with preserved ejection fraction: a nationwide cohort study
Salil V. Deo,Yogesh N.V. Reddy,Rosita Zakeri,Mohamad Karnib,Padmini Selvaganesan,Yakov Elgudin,Ahmet Kilic,Joseph Rubelowsky,Salah E. Altarabsheh,Mohammed Osman,Richard Josephson,Sri Krishna Madan Mohan,Brian L. Cmolik,Daniel I. Simon,Sanjay Rajagopalan,John G.F. Cleland,Jayakumar Sahadevan,Varun Sundaram +17 more
TL;DR: Despite the common occurrence of coronary artery disease (CAD) and heart failure with preserved ejection fraction (HFpEF), there is limited evidence to guide revascularization.
Journal ArticleDOI
Synchronized diaphragmatic stimulation: a case report of a novel extra‐cardiac intervention for chronic heart failure
Lee R. Goldberg,Ana Jorbenadze,Tamaz Shaburishvilli,Michael J. Mirro,Marat Fudim,Michel Zuber,Simon F. Stämpfli,Felix C. Tanner,Paul Erne,John G.F. Cleland +9 more
TL;DR: In a man with a history of myocardial infarctions resulting in heart failure and persistent New York Heart Association Class III symptoms despite standard therapies, the successful implantation of SDS resulting in improved quality of life, N‐terminal pro brain natriuretic peptide, cardiac function, and exercise tolerance through 12 months of follow-up.
Journal ArticleDOI
Whole blood transcriptomic profiling identifies molecular pathways related to cardiovascular mortality in heart failure
Mintu Nath,Simon P. R. Romaine,Andrea Koekemoer,Stephen E. Hamby,Tom R. Webb,Christopher P. Nelson,Marcos Castellanos-Uribe,M. Papakonstantinou,Stefan D. Anker,Chim C. Lang,Marco Metra,Faiez Zannad,Gerasimos Filippatos,Dirk J. van Veldhuisen,John G.F. Cleland,Leong L. Ng,Sean T. May,Federica M. Marelli-Berg,Adriaan A. Voors,James A. Timmons,Nilesh J. Samani +20 more
TL;DR: This work investigated whether whole blood transcriptomic profiling can provide new mechanistic insights into cardiovascular (CV) mortality in CHF.